VIVO BIO TECH | MODI RUBBER | VIVO BIO TECH/ MODI RUBBER |
|||
---|---|---|---|---|---|
P/E (TTM) | x | 37.4 | -7.6 | - | View Chart |
P/BV | x | 1.2 | 0.3 | 353.5% | View Chart |
Dividend Yield | % | 0.0 | 0.0 | - |
![]() ![]() |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
VIVO BIO TECH Mar-21 |
MODI RUBBER Mar-21 |
VIVO BIO TECH/ MODI RUBBER |
5-Yr Chart Click to enlarge
|
||
High | Rs | 71 | 211 | 33.9% | |
Low | Rs | 18 | 26 | 66.7% | |
Sales per share (Unadj.) | Rs | 38.6 | 1.1 | 3,485.0% | |
Earnings per share (Unadj.) | Rs | 4.2 | -2.7 | -156.3% | |
Cash flow per share (Unadj.) | Rs | 8.4 | -1.6 | -512.3% | |
Dividends per share (Unadj.) | Rs | 0 | 0 | - | |
Avg Dividend yield | % | 0 | 0 | - | |
Book value per share (Unadj.) | Rs | 30.6 | 173.3 | 17.7% | |
Shares outstanding (eoy) | m | 13.42 | 25.04 | 53.6% | |
Bonus / Rights / Conversions | 0 | 0 | - | ||
Price / Sales ratio | x | 1.2 | 107.1 | 1.1% | |
Avg P/E ratio | x | 10.5 | -43.8 | -24.0% | |
P/CF ratio (eoy) | x | 5.3 | -72.3 | -7.3% | |
Price / Book Value ratio | x | 1.5 | 0.7 | 212.1% | |
Dividend payout | % | 0 | 0 | - | |
Avg Mkt Cap | Rs m | 597 | 2,970 | 20.1% | |
No. of employees | `000 | NA | NA | - | |
Total wages/salary | Rs m | 86 | 41 | 207.5% | |
Avg. sales/employee | Rs Th | 0 | 0 | - | |
Avg. wages/employee | Rs Th | 0 | 0 | - | |
Avg. net profit/employee | Rs Th | 0 | 0 | - |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 518 | 28 | 1,867.8% | |
Other income | Rs m | 1 | 133 | 0.8% | |
Total revenues | Rs m | 519 | 161 | 322.6% | |
Gross profit | Rs m | 178 | -177 | -100.7% | |
Depreciation | Rs m | 56 | 27 | 208.6% | |
Interest | Rs m | 37 | 6 | 576.9% | |
Profit before tax | Rs m | 86 | -77 | -112.3% | |
Minority Interest | Rs m | 0 | 0 | - | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
Tax | Rs m | 29 | -9 | -329.6% | |
Profit after tax | Rs m | 57 | -68 | -83.7% | |
Gross profit margin | % | 34.3 | -637.3 | -5.4% | |
Effective tax rate | % | 34.1 | 11.6 | 293.6% | |
Net profit margin | % | 11.0 | -244.8 | -4.5% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 271 | 1,173 | 23.1% | |
Current liabilities | Rs m | 218 | 219 | 99.8% | |
Net working cap to sales | % | 10.1 | 3,441.7 | 0.3% | |
Current ratio | x | 1.2 | 5.4 | 23.1% | |
Inventory Days | Days | 0 | 51,391 | 0.0% | |
Debtors Days | Days | 51,413,598 | 1,041 | 4,940,676.1% | |
Net fixed assets | Rs m | 524 | 3,392 | 15.4% | |
Share capital | Rs m | 134 | 250 | 53.6% | |
"Free" reserves | Rs m | 277 | 4,088 | 6.8% | |
Net worth | Rs m | 411 | 4,338 | 9.5% | |
Long term debt | Rs m | 147 | 26 | 560.2% | |
Total assets | Rs m | 795 | 4,564 | 17.4% | |
Interest coverage | x | 3.3 | -11.1 | -30.3% | |
Debt to equity ratio | x | 0.4 | 0 | 5,913.7% | |
Sales to assets ratio | x | 0.7 | 0 | 10,720.8% | |
Return on assets | % | 11.8 | -1.3 | -873.5% | |
Return on equity | % | 13.8 | -1.6 | -884.0% | |
Return on capital | % | 22.1 | -1.6 | -1,367.3% | |
Exports to sales | % | 0 | 0 | - | |
Imports to sales | % | 0 | 0 | - | |
Exports (fob) | Rs m | NA | NA | - | |
Imports (cif) | Rs m | NA | NA | - | |
Fx inflow | Rs m | 19 | 0 | - | |
Fx outflow | Rs m | 42 | 3 | 1,648.2% | |
Net fx | Rs m | -23 | -3 | 917.0% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 142 | -58 | -243.6% | |
From Investments | Rs m | -228 | 16 | -1,472.4% | |
From Financial Activity | Rs m | 88 | -8 | -1,065.9% | |
Net Cashflow | Rs m | 1 | -51 | -2.7% |
Indian Promoters | % | 42.2 | 52.5 | 80.3% | |
Foreign collaborators | % | 0.0 | 10.2 | - | |
Indian inst/Mut Fund | % | 0.0 | 2.2 | - | |
FIIs | % | 0.0 | 0.2 | - | |
ADR/GDR | % | 0.0 | 0.0 | - | |
Free float | % | 57.8 | 37.3 | 155.0% | |
Shareholders | 12,632 | 13,612 | 92.8% | ||
Pledged promoter(s) holding | % | 0.0 | 0.0 | - |
Compare VIVO BIO TECH With: VA TECH WABAG DELTA CORP HEALTHCARE GLOBAL ENTER. YAARII DIGITAL INTEGRATED SANGHVI MOVERS
Asian share markets opened higher today as another round of weak US data provided a little hope that the Federal Reserve will temper its pace of interest rate hikes.